Theratechnologies (THTX) shares were up 50% in recent premarket activity Wednesday after the company said overnight that the US Food and Drug Administration approved its supplemental biologics license application for the new formulation of tesamorelin to be used as an injection.
The company said the tesamorelin injection is approved in the US for the reduction of excess abdominal fat in adults with HIV who have lipodystrophy.
The company plans to commercialize the new F8 formulation under the tradename EGRIFTA WR.
EGRIFTA WR only needs weekly reconstitution and requires less than half the administration volume as the current F4 formulation -- sold in the US as EGRIFTA SV -- which is reconstituted daily, the company said.
The new formulation, which is patent-protected in the US through 2033, will replace EGRIFTA SV.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。